pde1a  (BPS Bioscience)

Journal: International Journal of Nanomedicine

Article Title: Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients

doi: 10.2147/IJN.S27442

Figure Lengend Snippet: Properties of commercial carbon nanotubes as provided by suppliers

Article Snippet: MWNT 7 , 15–45 , N/A , 5–20 , N/A , >95 , Fe, S , NanoLab PD30L520 (batch 60310) , CVD.

Techniques:

Journal: Gastroenterology

Article Title: Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.

doi: 10.1053/j.gastro.2021.02.051

Figure Lengend Snippet: Figure 4. Sqle activates de novo lipogenesis via CA3 in NASH. (A) Silver staining results of co-IP by using Sqle tg mice liver protein. (B) The interaction between SQLE and CA3 was further confirmed by using Sqle tg mice liver protein and commercial recombinant human SQLE and CA3 protein. (C) Direct binding of SQLE and CA3 were confirmed using enzyme-linked immunosorbent assay. (D–E) Western blot analysis showed that SQLE stabilizes CA3 protein expression by inhibiting auto- phagy-lysosome–dependent protein degradation pathway. (F) CA3 overexpression increase intracellular Triglyceride level and protein expression of SREBP1C, FASN, and p- IkBa and p-P65 NF-kB subunit in LO2 and HKCI10 cells. (G) Silence CA3 expression reverse SQLE induced TG level and protein expression of FASN and p-P65. (H) Western blot analysis showed Acetazolamide reduced liver TG and protein expression of CA3 and reduced SQLE-induced protein expression of ACC, FASN, p-P65, and p- IkBa in SQLE-tg mice. (I) Western blot analysis showed that cholesterol treatment cannot increase Car3 protein expression. *P < .05; **P < .01, ***P < .001

Article Snippet: SiRNA of human CA3 (sc-60309) and control (siCTL) were ordered from Santa Cruz (Dallas, USA).

Techniques: Silver Staining, Co-Immunoprecipitation Assay, Recombinant, Binding Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Over Expression

Journal: Gastroenterology

Article Title: Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.

doi: 10.1053/j.gastro.2021.02.051

Figure Lengend Snippet: Figure 6. Pharmacologic inhibition of SQLE and CA3 synergistically ameliorated NASH development. (A) Schematic diagram of combined drug treatment in HFHC diet–induced mouse NASH model. Combined terbinafine and acetazolamide treatment significantly reduced liver weight and liver-to-body weight ratio. (B) Terbinafine plus Acetazolamide abolished HFHC diet– induced accumulation of liver triglyceride, FFA, and TBARS, (C) and accumulation of serum triglyceride, ALT, and AST and improved glucose tolerance test and ITT. (D) Liver histology showed that combined terbinafine plus acetazolamide syner- gistically attenuated steatohepatitis, lipid accumulation, and liver fibrosis (**P < .01; ***P < .001 vs PBS group). (E) Serum IL1a, IL1b, IL6, IL17, MCP-1, MIP-1b, and TNF-a concentration of 4 groups. (F) Western blot analysis showed that combined drug treatment decreased p-P65 and p-IkBa in HFHC-fed WT mice. (G) qPCR analysis indicated that terbinafine plus acetazolamide synergistically suppressed mRNA expression of genes involved in lipogenesis, triglyceride biosynthesis, and fibrosis. Scale bars, 100 mm. *P < .05; **P < .01; ***P < .001.

Article Snippet: SiRNA of human CA3 (sc-60309) and control (siCTL) were ordered from Santa Cruz (Dallas, USA).

Techniques: Inhibition, Concentration Assay, Western Blot, Expressing

Journal: Gastroenterology

Article Title: Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.

doi: 10.1053/j.gastro.2021.02.051

Figure Lengend Snippet: Figure 7. SQLE is up-regulated in human NASH and serum SQLE/CA3 are novel biomarkers for the clinical diagnosis of NASH. (A) SQLE mRNA and (B) protein expression was up-regulated in patients with NAFLD. (C) Serum SQLE concentration in 72 healthy people, 65 patients with steatosis, and 80 patients with NASH. (D) Correlation analysis between serum SQLE and clinical information of patients with NAFLD. (E) Serum CA3 concentration in 72 healthy people, 65 patients with steatosis, and 80 patients with NASH. (F) Correlation analysis between serum CA3 and clinical information of patients with NAFLD. (G) Correlation analysis between serum SQLE and serum CA3 concentration in patients with NAFLD. (H) AUROC of combined serum SQLE and CA3 in discriminating NAFLD and NASH in all patients.

Article Snippet: SiRNA of human CA3 (sc-60309) and control (siCTL) were ordered from Santa Cruz (Dallas, USA).

Techniques: Biomarker Discovery, Expressing, Concentration Assay

Journal: INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Article Title: PK-11195: A POTENTIAL DRUG IN LEUKEMIA TREATMENT

doi: 10.7897/2230-8407.050337

Figure Lengend Snippet: Figure 3: A) Western blot analysis using Ca III and GAPDH antibodies, of whole cell protein extracts derived from both untransfected and transfected 3T3-L1 cells with Ca III siRNA. The positions of 27 kDa Ca III and 35 kDa GAPDH proteins are labeled. B) Histogram of percentage viability (MTT assay) of untransfected and transfected 3T3-L1 cells with Ca III siRNA in the presence or absence of 70 µM PK-11195. The columns

Article Snippet: Anti-Ca III (P-17, sc-50715) and antiEvi1 (E-19, sc-54198), anti-GAPDH (V-18, sc-20357) and rabbit anti-goat IgG-HRP (sc-2768) antibodies and Ca III siRNA (sc-60310) were purchased from Santa Cruz Biotechnology, Inc. Caspase 3/7®Glo assay system (G8090) was purchased from Promega.

Techniques: Western Blot, Derivative Assay, Transfection, Labeling, MTT Assay